Literature DB >> 12052217

The impact of fatty acid oxidation on energy utilization: targets and therapy.

Gregory R Bebernitz1, Herbert F Schuster.   

Abstract

Utilization of fat as a long-term energy storage vehicle is crucial for the maintenance of cellular metabolism and is under intricate and many times redundant control mechanisms. Aberrations in the control of energy metabolism is apparent in diseases such as diabetes and obesity and is evident early on in patients with impaired glucose tolerance. Insulin resistance has been observed at the level of muscle, liver and adipose tissue. Hyperglycemia is the hallmark of diabetes and is characterized by decreased glucose disposal and increased glucose production, driven by enhanced and uncontrolled fatty acid oxidation (FAO). Mechanisms aimed at limiting the availability of substrates or the activity of processes involved in FAO should provide an immediate reduction in undesired glucose production in these individuals. Numerous targets are available which influence directly the metabolism of fat, including limiting availability of substrate to FAO, inhibiting oxidation of the fatty acid per se, and uncoupling the energy obtained during the oxidation of the fatty acid. These include antilipolytic agents which limit the availability of substrate, FAO inhibitors which limit fatty acid transport (carnitine palmitoyl transferase, CoA sequestration), FAO per se (beta oxidation), and agents which uncouple the energy of FAO (uncoupling proteins, beta3 agonists). These other targets which affect fatty acid metabolism indirectly will be discussed in this review with 184 references.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052217     DOI: 10.2174/1381612023394692

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  7 in total

1.  Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight gain, hyperlipidemia, and hepatic steatosis in db/db mice.

Authors:  Xiao-dong Zhang; Jian-wei Yan; Gui-rui Yan; Xiao-yun Sun; Jun Ji; Yi-ming Li; You-hong Hu; He-yao Wang
Journal:  Acta Pharmacol Sin       Date:  2010-11       Impact factor: 6.150

Review 2.  Evolving function and potential of pancreatic alpha cells.

Authors:  Violeta Stanojevic; Joel F Habener
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-10-08       Impact factor: 4.690

Review 3.  The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.

Authors:  Jonathan R S Arch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-09       Impact factor: 3.000

4.  Altering pyrroloquinoline quinone nutritional status modulates mitochondrial, lipid, and energy metabolism in rats.

Authors:  Kathryn Bauerly; Calliandra Harris; Winyoo Chowanadisai; James Graham; Peter J Havel; Eskouhie Tchaparian; Mike Satre; Joel S Karliner; Robert B Rucker
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

Review 5.  Is 5´-AMP-Activated Protein Kinase Both Jekyll and Hyde in Bladder Cancer?

Authors:  Wun-Jae Kim
Journal:  Int Neurourol J       Date:  2015-06-29       Impact factor: 2.835

6.  Mitochondria-targeted dodecyltriphenylphosphonium (C12TPP) combats high-fat-diet-induced obesity in mice.

Authors:  A V Kalinovich; C L Mattsson; M R Youssef; N Petrovic; M Ost; V P Skulachev; I G Shabalina
Journal:  Int J Obes (Lond)       Date:  2016-08-18       Impact factor: 5.095

7.  Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.

Authors:  Xing Jin; Seok Joong Yun; Pildu Jeong; Isaac Yi Kim; Wun-Jae Kim; Sunghyouk Park
Journal:  Oncotarget       Date:  2014-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.